Cognitive Enhancement Studies Cognitive improvement studies in 28-month-old mice (equivalent to elderly humans) using 10 mg/kg body weight administered 5x per week for 3 weeks demonstrated: Significantly faster escape hole finding in Box Maze tests (trials 4 and 5) Evidence of decreased brain inflammation Increased histone deacetylase 2 labeling indicating epigenetic pathway activation Preliminary reversal of age-related cognitive impairment Pain and Anxiety Modulation Anti-pain effects in mice at 0.5 mg/kg showed efficacy comparable to cimetidines human analgesic effects, affecting 7 anti-pain genes (increased) and 2 genes (decreased), with upregulated opioid receptors and related pain-modulating pathways
The active loss phase is typically 90 days, followed by a maintenance phase
Yes, based on ongoing response
A temporary Medicare GLP-1 Bridge program now covers Wegovy, Zepbound, and Foundayo at $50/month through December 31, 2027, but retatrutide isn't expected to be approved until late 2027 at the earliest, meaning it will likely miss this window
Keep a blood pressure log at home, especially during your first month of treatment, and report trends to your PlexusDx clinician before they become problematic
Inject the water slowly against the inner wall of the vial do not spray directly onto the peptide powder
